Linacon

Linagliptin, the active ingredient in Linacon, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients. GNH USA supplies Linacon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linacon is a DPP-4 inhibitor indicated for the management of type 2 diabetes mellitus, helping to improve glycaemic control. - Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels as monotherapy. - Type 2 diabetes mellitus (combined therapy): enhances overall glucose management when used with other antidiabetic agents. - Type 2 diabetes mellitus (diet and exercise adjunct): supports target HbA1c achievement alongside lifestyle measures.

Adverse reactions to Linacon may vary in frequency and severity.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory infection: cough, sore throat, or congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhoea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Angioedema: swelling of face, lips, or throat. - Severe allergic reaction: systemic symptoms requiring emergency care.

When prescribing Linacon, clinicians should consider several safety aspects. - Renal impairment: monitor renal function, although dose adjustment is not required. - Hepatic impairment: assess liver enzymes and use with caution in severe disease. - Cardiovascular disease: observe for any cardiovascular events, especially in high‑risk patients. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown safety; consider discontinuation. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Linacon may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce linagliptin exposure. - Co‑administration with another DPP‑4 inhibitor: duplicate therapy should be avoided.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia; monitor glucose levels. - Moderate CYP3A4 inducers (e.g., phenobarbital): may lower efficacy. - Diuretics: may affect renal clearance; observe renal function.